We are live on ! Find out more
USNA icon

Usana Health Sciences

176 hedge funds and large institutions have $658M invested in Usana Health Sciences in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 58 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

25% more capital invested

Capital invested by funds: $528M → $658M (+$131M)

19% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 58

5% more funds holding

Funds holding: 167176 (+9)

0.4% less ownership

Funds ownership: 54.5%54.09% (-0.4%)

87% less call options, than puts

Call options by funds: $176K | Put options by funds: $1.4M

Holders
176
Holders Change
+9
Holders Change %
+5.39%
% of All Funds
2.8%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
69
Reduced
58
Closed
14
Calls
$176K
Puts
$1.4M
Net Calls
-$1.23M
Net Calls Change
-$1.17M

USNA Hedge Fund Activity: Q1 2023 in Review

176 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Usana Health Sciences (USNA) for Q1 2023, worth a combined $658M — up 25% from $528M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new USNA positions and 14 closed out — a net gain of 10 holders — while 69 added to existing stakes and 58 trimmed.

The largest buyer was Pzena Investment Management, adding an estimated $6.06M. The largest seller was Invesco, cutting an estimated $7.69M.

  • 176 institutional investors held Usana Health Sciences (USNA) as of Q1 2023, up from 167 in Q4 2022.
  • Funds reported $658M of Usana Health Sciences stock for Q1 2023, up 25% quarter-over-quarter.
  • 24 funds opened new Usana Health Sciences positions in Q1 2023 and 14 closed out, a net change of +10 holders.
  • The largest Usana Health Sciences buyer in Q1 2023 was Pzena Investment Management, an estimated $6.06M added.
  • The largest Usana Health Sciences seller in Q1 2023 was Invesco, an estimated $7.69M sold.

Based on aggregated 13F filings for Q1 2023.